-
Posted by
Two Blokes Jul 8 -
Filed in
Stock
-
3 views
SAN DIEGO--(BUSINESS WIRE)-- #invivoscribe--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe's global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented.
